Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pharmacokinetics of highly ionized drugs. II. Methylene blue--absorption, metabolism, and excretion in man and dog after oral administration.

Literature DB >> 5044807

Pharmacokinetics of highly ionized drugs. II. Methylene blue--absorption, metabolism, and excretion in man and dog after oral administration.

A R DiSanto, J G Wagner.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：
Methylene Blue

Year: 1972 PMID： 5044807 DOI： 10.1002/jps.2600610710

Source DB: PubMed Journal: J Pharm Sci ISSN： 0022-3549 Impact factor: 3.534

Keyword Cloud
Cited

× No keyword cloud information.

32 in total

1. Methylene blue modulates β-secretase, reverses cerebral amyloidosis, and improves cognition in transgenic mice.

Authors: Takashi Mori; Naoki Koyama; Tatsuya Segawa; Masahiro Maeda; Nobuhiro Maruyama; Noriaki Kinoshita; Huayan Hou; Jun Tan; Terrence Town
Journal: J Biol Chem Date: 2014-08-25 Impact factor: 5.157

2. Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria.

Authors: Jens Rengelshausen; Jürgen Burhenne; Margit Fröhlich; Yorki Tayrouz; Shio Kumar Singh; Klaus-Dieter Riedel; Olaf Müller; Torsten Hoppe-Tichy; Walter E Haefeli; Gerd Mikus; Ingeborg Walter-Sack
Journal: Eur J Clin Pharmacol Date: 2004-10-13 Impact factor: 2.953

3. Aromatic small molecules remodel toxic soluble oligomers of amyloid beta through three independent pathways.

Authors: Ali Reza A Ladiwala; Jonathan S Dordick; Peter M Tessier
Journal: J Biol Chem Date: 2010-11-23 Impact factor: 5.157

4. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.

Authors: Serge Gauthier; Howard H Feldman; Lon S Schneider; Gordon K Wilcock; Giovanni B Frisoni; Jiri H Hardlund; Hans J Moebius; Peter Bentham; Karin A Kook; Damon J Wischik; Bjoern O Schelter; Charles S Davis; Roger T Staff; Luc Bracoud; Kohkan Shamsi; John M D Storey; Charles R Harrington; Claude M Wischik
Journal: Lancet Date: 2016-11-16 Impact factor: 79.321

5. Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models.

Authors: Emily Mitchell Sontag; Gregor P Lotz; Namita Agrawal; Andrew Tran; Rebecca Aron; Guocheng Yang; Mihaela Necula; Alice Lau; Steven Finkbeiner; Charles Glabe; J Lawrence Marsh; Paul J Muchowski; Leslie M Thompson
Journal: J Neurosci Date: 2012-08-08 Impact factor: 6.167

Pharmacokinetics of highly ionized drugs. II. Methylene blue--absorption, metabolism, and excretion in man and dog after oral administration.

1. Methylene blue modulates β-secretase, reverses cerebral amyloidosis, and improves cognition in transgenic mice.

2. Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria.

3. Aromatic small molecules remodel toxic soluble oligomers of amyloid beta through three independent pathways.

4. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.

5. Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models.

6. A new ancient irrigation therapy for childhood renal candidiasis.

7. High absolute bioavailability of methylene blue given as an aqueous oral formulation.

8. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines.

Review 9. Cellular and molecular actions of Methylene Blue in the nervous system.

10. Benzocaine-induced methemoglobinemia: a potentially fatal complication of transesophageal echocardiography.